Annovis Stock Analysis

ANVS -  USA Stock  

USD 8.61  0.37  4.12%

The big decline in price over the last few months for Annovis Bio could raise concerns from retail investors as the firm is trading at a share price of 8.61 on 21,725 in volume. The company directors and management failed to add value to investors and position the firm supply of money to exploit market volatility in April. However, diversifying your holdings with Annovis Bio or similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 4.5. This high volatility is attributed to the latest market swings and not-so-good earnings reports for some of the Annovis Bio partners.
Please continue to Trending Equities.
The Annovis Bio stock analysis report makes it easy to digest most publicly released information about Annovis Bio and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Annovis Stock analysis module also helps to analyze the Annovis Bio price relationship with some important fundamental indicators such as market cap and management efficiency.

Annovis Stock Analysis Notes

About 31.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.59. Some equities with similar Price to Book (P/B) outperform the market in the long run. Annovis Bio recorded a loss per share of 1.4. The entity had not issued any dividends in recent years. Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania. Annovis Bio operates under Biotechnology classification in the United States and is traded on New York Stock Exchange. It employs 3 people. For more info on Annovis Bio please contact Maria Maccecchini at 610 727 3913 or go to

Annovis Bio Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Annovis Bio's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Annovis Bio or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Annovis Bio generated a negative expected return over the last 90 days
Annovis Bio has high historical volatility and very poor performance
Annovis Bio has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 366.66 K. Net Loss for the year was (14.49 M) with profit before overhead, payroll, taxes, and interest of 173.72 K.
Annovis Bio currently holds about 45.69 M in cash with (9.13 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.6.
Annovis Bio has a poor financial position based on the latest SEC disclosures
Roughly 31.0% of the company shares are held by company insiders
Latest headline from Biogen Medicare Setback May Trigger Innovation And Partnerships - Seeking Alpha

Annovis Bio Upcoming and Recent Events

Earnings reports are used by Annovis Bio to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Annovis Bio previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report2nd of March 2022
Next Fiscal Quarter End31st of December 2021

Annovis Bio SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Annovis Bio prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Annovis Bio investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Annovis Bio specific information freely available to individual and institutional investors to make a timely investment decision.
4th of May 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
15th of November 2021
Financial Statements and Exhibits. Regulation FD Disclosure. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
12th of November 2021
Financial Statements and Exhibits. Regulation FD Disclosure
5th of October 2021
Financial Statements and Exhibits. Regulation FD Disclosure
11th of August 2021
Financial Statements and Exhibits. Regulation FD Disclosure
28th of July 2021
Financial Statements and Exhibits. Regulation FD Disclosure

Annovis Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Annovis Bio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Annovis Bio backward and forwards among themselves. Annovis Bio's institutional investor refers to the entity that pools money to purchase Annovis Bio's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Vanguard Group IncCommon Shares242.5 K3.2 M
Blackrock IncCommon Shares147.7 KM
Morgan StanleyCommon Shares110.1 K1.5 M
Millennium Management LlcCommon Shares62.7 K837 K
Two Sigma Advisers LpCommon Shares46.4 K619 K
Geode Capital Management LlcCommon Shares42 K561 K
Wescott Financial Advisory Group LlcCommon Shares41.6 K555 K
Note, although Annovis Bio's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Annovis Market Capitalization

The company currently falls under 'Micro-Cap' category with current market capitalization of 74.12 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Annovis Bio's market, we take the total number of its shares issued and multiply it by Annovis Bio's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Annovis Profitablity

Annovis Bio's profitability indicators refer to fundamental financial ratios that showcase Annovis Bio's ability to generate income relative to its revenue or operating costs. If, let's say, Annovis Bio is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Annovis Bio's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Annovis Bio's profitability requires more research than a typical breakdown of Annovis Bio's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2022
Return on Average Assets(0.39) (0.42) 
Return on Average Equity(0.40) (0.43) 
Return on Invested Capital 14.62  15.39 

Management Efficiency

The entity has return on total asset (ROA) of (33.58) % which means that it has lost $33.58 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (55.68) %, meaning that it created substantial loss on money invested by shareholders. Annovis Bio management efficiency ratios could be used to measure how well annovis bio manages its routine affairs as well as how well it operates its assets and liabilities. As of 05/24/2022, Return on Invested Capital is likely to grow to 15.39, while Return on Average Assets are likely to drop (0.42) . Annovis Bio Total Assets are relatively stable at the moment as compared to the past year. Annovis Bio reported last year Total Assets of 46 Million. As of 05/24/2022, Current Assets is likely to grow to about 49.6 M, while Return on Average Assets are likely to drop (0.42) .
Last ReportedProjected for 2022
Book Value per Share 5.83  6.30 
Enterprise Value over EBIT(7.00) (7.55) 
Enterprise Value over EBITDA(6.55) (7.07) 
Price to Book Value 3.20  3.81 
Tangible Assets Book Value per Share 6.03  4.83 
Enterprise Value95 M89.9 M
Tangible Asset Value46 M49.6 M

Technical Drivers

As of the 24th of May, Annovis Bio shows the risk adjusted performance of (0.19), and Mean Deviation of 3.57. Annovis Bio technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate and analyze data for nineteen technical drivers for Annovis Bio, which can be compared to its rivals. Please confirm Annovis Bio downside deviation, treynor ratio, as well as the relationship between the Treynor Ratio and expected short fall to decide if Annovis Bio is priced correctly, providing market reflects its regular price of 8.61 per share. Given that Annovis Bio has jensen alpha of (0.43), we suggest you to validate Annovis Bio's prevailing market performance to make sure the company can sustain itself at a future point.

Annovis Bio Price Movement Analysis

Illegal number of arguments. The output start index for this execution was zero with a total number of output elements of zero. The Mid-point over period is an average of Annovis Bio highest and lowest values attained during the given period.

Annovis Bio Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Annovis Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Annovis Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Annovis Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Annovis Bio Predictive Daily Indicators

Annovis Bio intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Annovis Bio stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Annovis Bio Forecast Models

Annovis Bio time-series forecasting models is one of many Annovis Bio's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Annovis Bio's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Annovis Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Annovis Bio stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Annovis shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Annovis Bio. By using and applying Annovis Stock analysis, traders can create a robust methodology for identifying Annovis entry and exit points for their positions.
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania. Annovis Bio operates under Biotechnology classification in the United States and is traded on New York Stock Exchange. It employs 3 people.

Current Annovis Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Annovis analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Annovis analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
70.0Strong Buy1Odds
Annovis Bio current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Annovis analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Annovis stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Annovis Bio, talking to its executives and customers, or listening to Annovis conference calls.
Annovis Analyst Advice Details

Annovis Stock Analysis Indicators

Annovis Bio stock analysis indicators help investors evaluate how Annovis Bio stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Annovis Bio shares will generate the highest return on investment. By understating and applying Annovis Bio stock analysis, traders can identify Annovis Bio position entry and exit signals to maximize returns.
Shares Percent Shares Out2.12%
Quick Ratio30.33
Fifty Two Week Low8.39
Short Percent Of Float3.07%
Forward Price Earnings-3.57
Float Shares5.64M
Fifty Two Week High132.00
Shares Short Prior Month279.58k
Average Daily Volume Last 10 Day32.22k
Average Daily Volume In Three Month40.96k
Fifty Day Average11.95
Two Hundred Day Average21.71
Please continue to Trending Equities. Note that the Annovis Bio information on this page should be used as a complementary analysis to other Annovis Bio's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.

Complementary Tools for Annovis Stock analysis

When running Annovis Bio price analysis, check to measure Annovis Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Annovis Bio is operating at the current time. Most of Annovis Bio's value examination focuses on studying past and present price action to predict the probability of Annovis Bio's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Annovis Bio's price. Additionally, you may evaluate how the addition of Annovis Bio to your portfolios can decrease your overall portfolio volatility.
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Is Annovis Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Annovis Bio. If investors know Annovis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Annovis Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Annovis Bio is measured differently than its book value, which is the value of Annovis that is recorded on the company's balance sheet. Investors also form their own opinion of Annovis Bio's value that differs from its market value or its book value, called intrinsic value, which is Annovis Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Annovis Bio's market value can be influenced by many factors that don't directly affect Annovis Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Annovis Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine Annovis Bio value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Annovis Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.